Table 31.
Characteristics of PSC Patients According to Baseline sIgG4 Concentration.
| Normal sIgG4 | Elevated sIgG4 | p-value | |
|---|---|---|---|
| (≤140 mg/dL) | (>140 mg/dL) | ||
| (n = 200) | (n = 34) | ||
| Age, years | 44 (37–51) | 49 (38–59) | 0.046 |
| Male | 63% (126) | 68% (23) | 0.70 |
| White race | 84% (168) | 97% (33) | 0.058 |
| Ulcerative colitis | 46% (91) | 56% (19) | 0.27 |
| UDCA use | 60% (119) | 59% (20) | >0.99 |
| ALT, U/L | 64 (36–112) | 58 (35–123) | 0.60 |
| Alkaline phosphatase, U/L | 260 (127–399) | 262 (158–430) | 0.31 |
| GGT, U/L | 236 (93–495) | 252 (114–662) | 0.50 |
| Bilirubin, μmol/L | 0.7 (0.5–1.1) | 0.7 (0.5–1.0) | 0.92 |
| INR | 1.0 (0.9–1.0) | 1.0 (0.9–1.0) | 0.88 |
| Albumin, g/dL | 4.1 (3.8–4.3) | 3.8 (3.5–4.2) | 0.010 |
| Platelets, ×103/μL | 248 (196–306) | 282 (237–347) | 0.030 |
| FibroTest | 0.41 (0.23–0.58) | 0.48 (0.24–0.64) | 0.20 |
| ELF | 9.46 (8.54–10.33) | 9.46 (8.84–10.84) | 0.25 |
| Serum LOXL2, pg/mL | 100 (70–146) | 113 (88–155) | 0.18 |
| Ishak 3–6 fibrosis | 50% (100) | 56% (19) | 0.58 |
| MELD | 7 (6–8) | 6.5 (6–8) | 0.81 |
| Mayo risk score | –0.135 (–0.615, 0.365) | 0.015 (–0.47, 1.11) | 0.15 |
All data are median (IQR) or % (n).